Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes

Leukemia

Volumn 21, Issue 11, 2007, Pages 2237-2239

  Kiladjian, J J ^a,b   Fenaux, P ^b   Caignard, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL INTERACTION; CELLULAR IMMUNITY; CHROMOSOME ABERRATION; CYTOTOXICITY; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 35548945403     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404868     Document Type: Editorial

References (25)

1. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: Response to immunosuppressive theraphy. Br J Haematol 1995; 91: 403-408.
2. Hebbar M, Kozlowski D, Wattel E, MAstrini S, Dievart M, Duclos B et al: Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia 1997; 11: 2188-2191.
3. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithmocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
4. Cerwenka A, Lanier L. Natural killer cells, viruses and cancer. Nat. Rev Immunol 2001; 1: 41-49.
5. Long E. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875-904.
6. Farag S, Fehniger,.T, Ruggeri L, Velardi A, Caligiuri M. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
7. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2632-2640.
8. Carayol G, Robin C, Bourhis J, Bennaceur-Griscelli A, Chouaib S, Coulombel L et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol 1998; 28: 1991-2000.
9. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990; 76: 401-408.
10. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-3667.
11. Baron F, Turhan AG, Giron-Michel J, Azzarone B, Bentires-Alj M, Bours V et al. Leukemic target susceptibility to natural killer cytotoxicity: Relationship with BCR-ABL expression. Blood 2002; 99: 2107-2113.
12. Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B et al. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. Cancer Res 2005; 65: 2914-2920.
13. Cebo C, Da Rocha S, Wittnebel S, Turhan AG, Abdelali J, Caillat-Zucman S et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J Immunol 2006; 176: 864-872.
14. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006; 214: 202-218.
15. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-206.
16. Das H, Wang L, Kamath A, Bukowski J. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001; 98: 1616-1618.
17. Brandes M, Willimann K, Lang AB, Nam KH, Jin C, Brenner MB et al. Flexible migration program regulates gamma delta T-cell involvement in humoral immunity. Blood 2003; 102: 3693-3701.
18. Viey E, Laplace C, Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2005; 5: 973-986.
19. Carayol G, Giron-Michel J, Azzarone B, Castagna L, Cambier N, Mishal Z et al. Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. Oncogene 2000; 19: 2758-2766.
20. Kiladjian J, Bourgeois E, Bourhis J, Chouaib S, Fenaux P, Caignard A. Impaired natural killer cell differentiation in myelodysplastic syndromes. Blood 2003; 102(Suppl 1): 162a.
21. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463-470.
22. Epling-Burnette PK, Bai F, Painter JS, Rollison D, Salih HR, Krusch M et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109: 4816-4824.
23. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E et al. CD56dimCD1 6neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005; 19: 835-840.
24. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D. NK cells: Innate immunity against hematological malignancies? Trends Immunol 2004; 25: 328-333.
25. Malmberg KJ. Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004; 53: 879-892.